Medpace Holdings, Inc. (NASDAQ:MEDP) Receives $380.56 Average PT from Analysts

Shares of Medpace Holdings, Inc. (NASDAQ:MEDP) have earned a consensus recommendation of “Hold” from the eleven research firms that are presently covering the company, MarketBeat.com reports. Six investment analysts have rated the stock with a hold rating and five have given a buy rating to the company. The average 1 year price objective among analysts that have covered the stock in the last year is $380.56.

Several equities analysts have commented on MEDP shares. StockNews.com cut shares of Medpace from a “buy” rating to a “hold” rating in a research report on Friday, September 27th. Jefferies Financial Group cut shares of Medpace from a “buy” rating to a “hold” rating and decreased their price objective for the stock from $415.00 to $345.00 in a research report on Wednesday, September 25th. UBS Group cut shares of Medpace from a “buy” rating to a “neutral” rating and decreased their price objective for the stock from $420.00 to $350.00 in a research report on Friday, September 27th. Robert W. Baird lifted their price objective on shares of Medpace from $349.00 to $354.00 and gave the stock a “neutral” rating in a research report on Monday, November 25th. Finally, Redburn Atlantic started coverage on shares of Medpace in a research report on Monday, October 14th. They set a “buy” rating and a $404.00 price objective for the company.

Medpace Stock Performance

NASDAQ:MEDP opened at $337.35 on Friday. The stock has a market capitalization of $10.48 billion, a P/E ratio of 29.54, a PEG ratio of 1.80 and a beta of 1.36. The company has a 50 day moving average price of $340.52 and a 200 day moving average price of $357.30. Medpace has a fifty-two week low of $284.32 and a fifty-two week high of $459.77.

Medpace (NASDAQ:MEDP) last issued its quarterly earnings results on Monday, October 21st. The company reported $3.01 EPS for the quarter, beating the consensus estimate of $2.77 by $0.24. Medpace had a net margin of 17.66% and a return on equity of 50.87%. The company had revenue of $533.32 million during the quarter, compared to analysts’ expectations of $540.99 million. During the same quarter last year, the company posted $2.22 EPS. The firm’s revenue was up 8.3% compared to the same quarter last year. Research analysts forecast that Medpace will post 11.93 earnings per share for the current fiscal year.

Institutional Trading of Medpace

Hedge funds and other institutional investors have recently made changes to their positions in the company. Stone House Investment Management LLC purchased a new stake in Medpace during the third quarter worth about $33,000. Ashton Thomas Securities LLC purchased a new stake in Medpace during the third quarter worth about $37,000. Capital Performance Advisors LLP purchased a new stake in Medpace during the third quarter worth about $46,000. Ashton Thomas Private Wealth LLC purchased a new stake in Medpace during the second quarter worth about $52,000. Finally, True Wealth Design LLC boosted its holdings in Medpace by 16,800.0% during the third quarter. True Wealth Design LLC now owns 169 shares of the company’s stock worth $56,000 after buying an additional 168 shares in the last quarter. Hedge funds and other institutional investors own 77.98% of the company’s stock.

Medpace Company Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.